Phosphatidylserine Supplement Facts Label Review for US Supplement Brands

North American phosphatidylserine buyers usually clear source, MOQ, packaging, COA, and supplier-qualification questions first. Then the project reaches artwork, private-label transfer, or contract-manufacturer review and one narrower issue starts delaying approval: how exactly should phosphatidylserine appear on a U.S. supplement label, and where should soy or sunflower source wording be controlled?

The short answer is that phosphatidylserine should be handled as a Supplement Facts, source-routing, and allergen-control workflow, not as a casual artwork cleanup. FDA's Dietary Supplement Labeling Guide says dietary ingredients without Daily Values, such as phosphatidylserine, must be listed in the Supplement Facts panel by common or usual name with the amount per serving and the footnote "Daily Value Not Established." The same guidance says a dietary supplement may identify the source of a dietary ingredient in the panel, and that if the source ingredient is identified there, it generally does not need to be repeated outside the panel.

That matters because phosphatidylserine projects often move across procurement, QA, regulatory, brand, and contract-manufacturing teams. One group may still be using the shorthand "PS" while another drafts "soy phosphatidylserine" on a mockup. If the route and label logic are not locked together, the artwork review becomes slow.

This article is written for U.S. ingredient importers, supplement manufacturers, private-label brands, distributors, procurement managers, QA teams, and regulatory reviewers handling soy PS, sunflower PS, or general PS projects. It focuses on supplier qualification, label-prep workflow, and document control. It does not provide legal advice and it does not make medical treatment claims.

Where Nutranexa is mentioned, only verified site facts are used. The current site identifies the operating company as Shandong Baianrui Biopharmaceutical Co., Ltd., founded in 2013, operating a 110,000+ m2 campus, and primarily serving Europe and North America. It provides separate buyer paths for Phosphatidylserine, Soja Phosphatidylserine, and Tournesol Phosphatidylserine, along with Qualité & R&D, Fabrication, and Contacter le service commercial pages for current document requests. Final label approval should still depend on the exact route, the finished serving, and the buyer's own U.S. review path.

The Short Answer Buyers Need First

If your team is approving phosphatidylserine for a U.S. dietary supplement label, the cleanest workable process is:

1. Fix the exact route first: general PS, soy PS, or sunflower PS.
2. List phosphatidylserine in the Supplement Facts panel as an other dietary ingredient with the amount per serving and Daily Value Not Established.
3. Decide whether the source should be shown in the panel, for example by using parenthetical wording such as a source identified from soy lecithin or sunflower lecithin.
4. Check whether soy allergen disclosure is already satisfied within Supplement Facts or needs to appear in an ingredient list or Contains statement.
5. Match the artwork to the current specification, customer questionnaire, and manufacturing handoff file before approval.

That is the operational point buyers often miss. U.S. label review is not only a graphic-design task. It is the control that keeps the finished serving, source route, and allergen logic aligned to the same commercial item.

Why PS Label Declaration Is Its Own Buyer Task

Phosphatidylserine is an other dietary ingredient and belongs in Supplement Facts

The first reason this deserves its own workflow is that phosphatidylserine is not just background marketing copy. FDA's Dietary Supplement Labeling Guide says other dietary ingredients without established Daily Values, including phosphatidylserine, must be listed in the Supplement Facts panel by common or usual name with the amount by weight per serving. FDA's claims guidance separately says a brand may state that a product contains phosphatidylserine outside the panel, but only when the statement gives the specific amount and does not imply a Daily Value that does not exist.

That means the label review should begin with panel placement, not with front-label copy. Buyers should be able to confirm the serving size, the declared amount per serving, the naming logic, and whether the route being sold is the route represented in the panel.

This is not theoretical. In a March 8, 2023 warning letter, FDA cited a supplement label that listed phosphatidylserine outside the Supplement Facts panel rather than inside it with the quantitative amount per serving. The business lesson is simple: do not assume a clean-looking mockup is structurally correct just because the ingredient name appears somewhere on the package.

Source wording and soy allergen disclosure create a second review layer

The second reason PS label review deserves its own workflow is that source identity changes the file. FDA's dietary supplement labeling guidance says the source ingredient that supplies a dietary ingredient may be identified in the Supplement Facts label, and if it is identified there, it generally does not need to be listed again outside the panel.

Soy routes create one more layer because soy is a major food allergen under FDA's food-allergen framework. FDA's food-allergy materials say a major allergen can be declared by placing the food source in parentheses after the ingredient, or by using a separate Contains statement adjacent to the ingredient list. FDA's allergen Q&A for dietary supplements also says that when the allergen source is already declared within Supplement Facts, firms usually do not need to repeat it elsewhere, unless they choose to use a Contains statement and therefore must include all major allergens there.

That is why source wording and allergen review should be separated from generic specification approval:

The Six-Part Workflow for Reviewing a PS Supplement Facts Label

Lock the exact phosphatidylserine route and serving basis first

Before reviewing any label artwork, write down the exact route and serving basis in one approval note. Is the project using general PS, soy PS, or sunflower PS? Is the label being reviewed for one capsule, two capsules, one stick pack, or another serving format?

This matters because artwork often stabilizes faster than sourcing. QA may be reviewing a soy-source specification while marketing is already using a generic PS label. If the serving basis and source route are unstable, the panel cannot be reviewed as final.

The opening review note should usually record:

• exact product route
• serving size under review
• target amount of phosphatidylserine per serving
• whether the label is for early mockup, final artwork, or contract-manufacturer transfer
• which downstream party asked for the label file

Put phosphatidylserine in the right place and use the right naming logic

The second step is structural. FDA's guidance says phosphatidylserine is an other dietary ingredient and should appear inside Supplement Facts with the amount by weight per serving and the no-Daily-Value footnote.

A buyer should check:

1. Is phosphatidylserine inside the Supplement Facts panel rather than treated as stray front-panel copy?
2. Is the amount per serving stated in metric units?
3. Does the panel use a stable name that matches the route decision?
4. Is Daily Value Not Established handled correctly for the PS line?

Decide where source wording should appear for soy or sunflower routes

Once the panel placement is correct, decide where source wording belongs. FDA says the source ingredient may be identified in the Supplement Facts panel. In practical B2B terms, a U.S. team usually has three workable questions: should the panel say only phosphatidylserine, should it identify a source in parentheses, and if not, where will the ingredient list carry it?

For soy and sunflower routes, this is not a cosmetic preference. It is the point where procurement, regulatory, and customer-facing files meet.

The right answer depends on the exact project, but the review logic should stay disciplined:

Handle soy allergen disclosure without duplicating the file blindly

This is where many U.S. label reviews become messy. Soy-source PS projects often trigger a reflex to repeat soy in every possible place. FDA's food-allergy materials say the allergen source must appear at least once in a compliant manner. FDA's dietary-supplement allergen guidance explains that if the source ingredient or the allergen source is already declared within Supplement Facts, that usually satisfies the requirement without repeating it elsewhere. But if the brand uses a Contains statement, that statement must include all major allergens present.

For buyers, the practical question is not "how many times can we print soy?" The question is narrower:

• where is soy already declared
• does that declaration clearly connect to the PS route
• is the brand also using a Contains statement for broader allergen control
• will the contract manufacturer or customer require one form rather than another

That is why this article sits beside, not inside, Phosphatidylserine Allergen Statement Checklist for US and EU Ingredient Buyers. The allergen statement answers the supplier-file question. This article answers the U.S. label-routing question.

Match artwork to the specification, COA path, and customer questionnaire

The fifth step is the one procurement teams often skip. A technically legal label line can still be the wrong commercial label if it belongs to the wrong route. Before artwork approval, compare the label file to:

• the current specification
• the COA path or representative batch-document logic
• any customer or contract-manufacturer questionnaire already in circulation
• the route-specific support files already approved internally

This matters because the label may become the reference document downstream. If the label says sunflower phosphatidylserine while the approved item is still generic PS or a soy route, the artwork creates avoidable rework. If the customer questionnaire expects soy-linked allergen logic, but the label file removed the route wording, QA will have to reopen the file later.

Need a Current Route-Specific Label Support File?

If your team is still reviewing mockups that say only "PS" while procurement, QA, or a contract manufacturer is asking whether the route is soy or sunflower, stop before the artwork becomes an approval shortcut. Use Nutranexa's contact page to request the current route-specific specification path, COA-review path, and label-support file for the exact phosphatidylserine route under review.

The fastest inquiries usually include the route, serving size, target amount per serving, target market, and whether the request is coming from a brand, importer, distributor, or contract manufacturer.

Common Mistakes in Phosphatidylserine Label Review

Most failures here are file-control failures, not design failures.

1. Leaving phosphatidylserine outside Supplement Facts as if it were optional marketing text.
2. Approving a generic PS label while procurement is still switching between soy and sunflower routes.
3. Repeating source wording randomly across Supplement Facts, ingredient list, and customer files without deciding which line is actually controlled.
4. Treating soy allergen disclosure as separate from the source decision.
5. Forgetting that an amount claim outside Supplement Facts still needs to be specific and consistent with the panel.
6. Letting final artwork move forward before QA has checked the label against the approved specification and downstream questionnaire.

The practical fix is simple: keep one question at the center of the file. What exact phosphatidylserine route, amount-per-serving line, and allergen-routing logic is this U.S. label actually approving?

How Verified Nutranexa Facts Fit This Workflow

For buyers evaluating Nutranexa, several verified site facts support a cleaner U.S. label-review process.

First, the site already separates Phosphatidylserine, Soja Phosphatidylserine, and Tournesol Phosphatidylserine into distinct buyer paths. That makes it easier to attach a Supplement Facts draft to one stable route instead of one vague PS category.

Second, the site confirms practical qualification facts that are safe to reuse in supplier screening: the company was founded in 2013, operates a 110,000+ m2 campus, and primarily serves Europe and North America.

Third, Nutranexa's public site routes buyers through Qualité & R&D, Fabrication, and Contacter le service commercial instead of implying that one public page settles every downstream label question.

Fourth, the site provides verified commercial handling facts for phosphatidylserine, including 25 kg MOQ et 25 kg net par fût packaging, together with public COA/specification evidence and factory, packaging, and dispatch imagery. Those facts help supplier qualification, but they do not replace the label review described in this article.

Sources

• FDA: Dietary Supplement Labeling Guide, Chapter IV. Nutrition Labeling
• FDA: Dietary Supplement Labeling Guide, Chapter VI. Claims
• FDA: Food Allergies
• FDA: Questions and Answers Regarding Food Allergen Labeling, Edition 5
• eCFR: 21 CFR 101.36, Nutrition labeling of dietary supplements
• eCFR: 21 CFR Part 111, Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
• FDA Warning Letter: Spartan Enterprises Inc. dba Watershed Wellness Center, March 8, 2023

FAQ

Does phosphatidylserine belong in Supplement Facts on a U.S. dietary supplement label?

Yes. FDA's dietary-supplement labeling guidance treats phosphatidylserine as an other dietary ingredient without an established Daily Value, so it should be listed in Supplement Facts with the amount per serving and the no-Daily-Value footnote.

If soy is already identified in Supplement Facts, do we still need it again in the ingredient list?

Usually not, if the allergen source is already declared in a compliant way within Supplement Facts. But if the brand also uses a Contains statement, that statement should include all major allergens present.

What should buyers request from Nutranexa before approving phosphatidylserine label artwork?

Request the exact route-specific specification path, the current COA-review path, and any source-related label-support file for the quoted phosphatidylserine route, then match those files to the serving size and final artwork under review.

Conclusion

Phosphatidylserine label review becomes manageable when buyers stop treating it as a last-minute design edit and start treating it as a route-specific Supplement Facts and allergen-control task.

The strongest U.S. workflow is practical: lock the route first, place phosphatidylserine correctly in Supplement Facts, decide intentionally where soy or sunflower source wording belongs, check whether soy allergen disclosure is already satisfied, and only then approve the artwork against the current specification and downstream questionnaire.

That process helps U.S. supplement brands, contract manufacturers, distributors, and QA teams avoid a common failure pattern: the artwork looks finished, but nobody can show that the phosphatidylserine line on the label actually belongs to the exact ingredient route being purchased.

Étapes suivantes recommandées

• Passez en revue le Phosphatidylserine page produit.
• Comparer Soy PS et Sunflower PS.
• Vérifier preuve de fabrication et Qualité & R&D.